In vivo evaluation of a new β-tricalcium phosphate bone substitute in a rabbit femur defect model

Kam Kong Chan, Chia Hsien Chen, Lien Chen Wu, Yi-Jie Kuo, Chun Jen Liao, Chang-Jung Chiang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Calcium phosphate ceramics, of a similar composition to that of mineral bone, and which possess the properties of bioactivity and osteoconductivity, have been widely used as substitutes for bone graft in orthopedic, plastic and craniofacial surgeries. A synthetic β-tricalcium phosphate, Osteocera™, a recently developed bone graft substitute, has been used in this study. To evaluate the affinity and efficacy of Osteocera™ as bone defect implant, we used a New Zealand white rabbit femur defect model to test the osteoconductivity of this new bone substitute. Alternative commercially available bone substitutes, Triosite® and ProOsteon500, were used as the control materials. These three bone substitutes show good biocompatibility, and no abnormal inflammation either infection was seen at the implantation sites. In the histological and histomorphometric images, newly formed bone grew into the peripheral pores in the bone substitutes. After six months implantation, the volume of bone formation was found to be 20.5 ± 5.2%, 29.8 ± 6.5% and 75.5 ± 4.9% of the potential total cavity offered by ProOsteon500, Triosite® and Osteocera™, respectively. The newly formed bone area within the femur defect section for Osteocera™ was significantly larger than ProOsteon500 and Triosite®. We concluded that Osteocera™ shows better bioresorbability, biocompatibility and osteoconductivity in the rabbit femur defect model.

Original languageEnglish
Article number1550028
JournalBiomedical Engineering - Applications, Basis and Communications
Volume27
Issue number3
DOIs
Publication statusPublished - Jun 29 2015

Fingerprint

Bone Substitutes
Femur
Bone
Phosphates
Rabbits
Defects
Bone and Bones
Biocompatibility
Grafts
Transplants
Orthopedics
Ceramics
Plastic Surgery
Bioactivity
Osteogenesis
Surgery
Minerals
tricalcium phosphate
Plastics
Inflammation

Keywords

  • Bone defect healing
  • New bone substitute
  • β-tricalcium phosphate (β-TCP)

ASJC Scopus subject areas

  • Biophysics
  • Biomedical Engineering
  • Bioengineering

Cite this

@article{d29cb17bb48844f1a799b52116a6af0a,
title = "In vivo evaluation of a new β-tricalcium phosphate bone substitute in a rabbit femur defect model",
abstract = "Calcium phosphate ceramics, of a similar composition to that of mineral bone, and which possess the properties of bioactivity and osteoconductivity, have been widely used as substitutes for bone graft in orthopedic, plastic and craniofacial surgeries. A synthetic β-tricalcium phosphate, Osteocera™, a recently developed bone graft substitute, has been used in this study. To evaluate the affinity and efficacy of Osteocera™ as bone defect implant, we used a New Zealand white rabbit femur defect model to test the osteoconductivity of this new bone substitute. Alternative commercially available bone substitutes, Triosite{\circledR} and ProOsteon500, were used as the control materials. These three bone substitutes show good biocompatibility, and no abnormal inflammation either infection was seen at the implantation sites. In the histological and histomorphometric images, newly formed bone grew into the peripheral pores in the bone substitutes. After six months implantation, the volume of bone formation was found to be 20.5 ± 5.2{\%}, 29.8 ± 6.5{\%} and 75.5 ± 4.9{\%} of the potential total cavity offered by ProOsteon500, Triosite{\circledR} and Osteocera™, respectively. The newly formed bone area within the femur defect section for Osteocera™ was significantly larger than ProOsteon500 and Triosite{\circledR}. We concluded that Osteocera™ shows better bioresorbability, biocompatibility and osteoconductivity in the rabbit femur defect model.",
keywords = "Bone defect healing, New bone substitute, β-tricalcium phosphate (β-TCP)",
author = "Chan, {Kam Kong} and Chen, {Chia Hsien} and Wu, {Lien Chen} and Yi-Jie Kuo and Liao, {Chun Jen} and Chang-Jung Chiang",
year = "2015",
month = "6",
day = "29",
doi = "10.4015/S1016237215500283",
language = "English",
volume = "27",
journal = "Journal of Chinese Corrosion Engineering",
issn = "1016-2372",
publisher = "World Scientific Publishing Co. Pte Ltd",
number = "3",

}

TY - JOUR

T1 - In vivo evaluation of a new β-tricalcium phosphate bone substitute in a rabbit femur defect model

AU - Chan, Kam Kong

AU - Chen, Chia Hsien

AU - Wu, Lien Chen

AU - Kuo, Yi-Jie

AU - Liao, Chun Jen

AU - Chiang, Chang-Jung

PY - 2015/6/29

Y1 - 2015/6/29

N2 - Calcium phosphate ceramics, of a similar composition to that of mineral bone, and which possess the properties of bioactivity and osteoconductivity, have been widely used as substitutes for bone graft in orthopedic, plastic and craniofacial surgeries. A synthetic β-tricalcium phosphate, Osteocera™, a recently developed bone graft substitute, has been used in this study. To evaluate the affinity and efficacy of Osteocera™ as bone defect implant, we used a New Zealand white rabbit femur defect model to test the osteoconductivity of this new bone substitute. Alternative commercially available bone substitutes, Triosite® and ProOsteon500, were used as the control materials. These three bone substitutes show good biocompatibility, and no abnormal inflammation either infection was seen at the implantation sites. In the histological and histomorphometric images, newly formed bone grew into the peripheral pores in the bone substitutes. After six months implantation, the volume of bone formation was found to be 20.5 ± 5.2%, 29.8 ± 6.5% and 75.5 ± 4.9% of the potential total cavity offered by ProOsteon500, Triosite® and Osteocera™, respectively. The newly formed bone area within the femur defect section for Osteocera™ was significantly larger than ProOsteon500 and Triosite®. We concluded that Osteocera™ shows better bioresorbability, biocompatibility and osteoconductivity in the rabbit femur defect model.

AB - Calcium phosphate ceramics, of a similar composition to that of mineral bone, and which possess the properties of bioactivity and osteoconductivity, have been widely used as substitutes for bone graft in orthopedic, plastic and craniofacial surgeries. A synthetic β-tricalcium phosphate, Osteocera™, a recently developed bone graft substitute, has been used in this study. To evaluate the affinity and efficacy of Osteocera™ as bone defect implant, we used a New Zealand white rabbit femur defect model to test the osteoconductivity of this new bone substitute. Alternative commercially available bone substitutes, Triosite® and ProOsteon500, were used as the control materials. These three bone substitutes show good biocompatibility, and no abnormal inflammation either infection was seen at the implantation sites. In the histological and histomorphometric images, newly formed bone grew into the peripheral pores in the bone substitutes. After six months implantation, the volume of bone formation was found to be 20.5 ± 5.2%, 29.8 ± 6.5% and 75.5 ± 4.9% of the potential total cavity offered by ProOsteon500, Triosite® and Osteocera™, respectively. The newly formed bone area within the femur defect section for Osteocera™ was significantly larger than ProOsteon500 and Triosite®. We concluded that Osteocera™ shows better bioresorbability, biocompatibility and osteoconductivity in the rabbit femur defect model.

KW - Bone defect healing

KW - New bone substitute

KW - β-tricalcium phosphate (β-TCP)

UR - http://www.scopus.com/inward/record.url?scp=84930018988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930018988&partnerID=8YFLogxK

U2 - 10.4015/S1016237215500283

DO - 10.4015/S1016237215500283

M3 - Article

AN - SCOPUS:84930018988

VL - 27

JO - Journal of Chinese Corrosion Engineering

JF - Journal of Chinese Corrosion Engineering

SN - 1016-2372

IS - 3

M1 - 1550028

ER -